MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

CRISPR Therapeutics AG

Abierto

SectorSanidad

38.39 -0.88

Resumen

Variación precio

24h

Actual

Mínimo

37.92

Máximo

39.09

Métricas clave

By Trading Economics

Ingresos

49M

-37M

Ventas

34M

35M

BPA

-0.44

Margen de beneficios

-106.603

Empleados

393

EBITDA

46M

-60M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+83.81% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

3.3B

Apertura anterior

39.27

Cierre anterior

38.39

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

CRISPR Therapeutics AG Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

26 sept 2024, 16:08 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Pfizer's Strategy Looks Shakier After Sickle-Cell Disappointment -- Barrons.com

26 sept 2024, 14:20 UTC

Adquisiciones, fusiones, absorciones

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. -- IBD

Comparación entre iguales

Cambio de precio

CRISPR Therapeutics AG previsión

Precio Objetivo

By TipRanks

83.81% repunte

Estimación a 12 Meses

Media 71.89 USD  83.81%

Máximo 120 USD

Mínimo 32 USD

De acuerdo con 19 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para CRISPR Therapeutics AG Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

19 ratings

12

Comprar

6

Mantener

1

Vender

Puntuación técnica

By Trading Central

38.5 / 39.27Soporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.